Novacept

Novacept was a medical device company dedicated to developing minimally invasive treatments for women's health conditions, specifically focusing on abnormal uterine bleeding. The company's flagship product, the NovaSure Endometrial Ablation System, utilizes radiofrequency energy to ablate the endometrial lining of the uterus as a treatment for menorrhagia. This technology provided a significant alternative to more invasive procedures like hysterectomy, offering a faster recovery time and high patient satisfaction. Novacept was acquired by Cytyc Corporation in 2004 for approximately $325 million. Following Cytyc's subsequent merger with Hologic in 2007, the NovaSure system remains a leading global brand in the gynecological surgical market.